Epigenetic silencing and pharmacological inhibition of EIF5A2 foster venetoclax sensitivity in acute myeloid leukaemia

Documenti analoghi

• Azacitidine–venetoclax in unfit acute myeloid leukaemia: One size does not fit all
  di: Felicetto Ferrara
  Pubblicazione: (2026)
• The heart of VIALE‐A: Cardiac complications of hypomethylating agents and venetoclax in acute myeloid leukaemia
  di: Shyam A. Patel
  Pubblicazione: (2024)
• Cardiac events in newly diagnosed acute myeloid leukaemia during treatment with venetoclax + hypomethylating agents
  di: Isla M. Johnson, et al.
  Pubblicazione: (2024)
• Salvage monotherapy with venetoclax after failure from a single course of standard induction chemotherapy for acute myeloid leukaemia
  di: Pierre‐Yves Sansen, et al.
  Pubblicazione: (2024)
• Fungal infection frequency in newly diagnosed acute myeloid leukaemia patients treated with venetoclax plus azacitidine with or without antifungal prophylaxis
  di: Barbora Weinbergerová, et al.
  Pubblicazione: (2024)